Sun, Dec 21, 2014, 3:54 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Array BioPharma, Inc. Message Board

  • bladerunner1717 bladerunner1717 May 17, 2013 5:44 AM Flag

    ARRY at BOA/ML conference

    ARRY @ BAML (5/16/13)

    1. Additional data on ARRY-520 + carfilzomib combo will be presented at EHA (believe in a few weeks) but sounds like the really mature data will be presented at ASH in December.

    2. More buzz for the Phase 2 selumetinib uveal melanoma data that is an oral presentation at ASCO. Data will be unveiled at the presentation. Squarer implied the data would be good and said there could be a fast path to market for selumetinib here. (The other oral presentation is for selumetinib+DTIC in BRAF melanoma; I saw the abstract and while PFS looked very good for selumetinib+DTIC, the OS benefit seemed to be minimal.)

    3. Another ASCO presentation (poster) is for MEK162 plus NVS' BRAF inhibitor in BRAF melanoma. Squarer alluded to the safety advantages of the combo relative to competition.

    4. Reference to an MDS patient that has been on ARRY-614 for 3 years now and now has a "practical cure." Patient had failed both Vidaza and Dacogen, which is patient population ARRY is pursuing with 614.

    Bladerunner (thanks to McBio for this)

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
4.86+0.06(+1.25%)Dec 19 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Under Armour, Inc.
NYSEFri, Dec 19, 2014 4:04 PM EST
ImmunoGen, Inc.
NASDAQFri, Dec 19, 2014 4:00 PM EST
Auspex Pharmaceuticals, Inc.
NASDAQFri, Dec 19, 2014 4:00 PM EST